United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As quoted in the press release: As previously announced, the effectiveness of …
United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.
As quoted in the press release:
As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The requisite waiting period expired on October 15, 2018, and the agreement became effective the same day.